Jasper Therapeutics Inc (JSPR) Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy Jasper Therapeutics Inc (JSPR) following the 2026 Q2 hedge fund 13F filings?

As of today, JSPR has moved -5.5% since the 2026 Q2 13F filing date (August 14, 2026), compared to +3.5% for the XLV sector ETF — an outperformance of -9.0%. Since the quarter end (June 30, 2026), JSPR gained +77.3% vs +9.2% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Jasper Therapeutics Inc (JSPR)

43 + Investors. Track Smart Money conviction in JSPR. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — JSPR

Based on 56 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds added JSPR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🔻

Below peak — only 66% of 3.0Y high

66% of all-time peak

Only 56 funds hold JSPR today versus a peak of 85 funds at 2024 Q4 — just 66% of the maximum. Low institutional ownership can mean the stock is out of favor, but it also means there's a large pool of potential buyers if sentiment turns.

📉

Outflows — 16% fewer funds vs a year ago

fund count last 6Q

11 fewer hedge funds hold JSPR compared to a year ago (-16% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.

🟡

Slight buying edge — 53% buying

28 buying25 selling

Last quarter: 28 funds bought or added vs 25 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

➡️

Steady new buyers — ~12 new funds per quarter

new funds entering per quarter

Funds opening this position for the first time: 16 → 16 → 10 → 12. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.

📌

Mixed — 30% long-term, 39% new

■ 30% conviction (2yr+) ■ 30% medium ■ 39% new

Of the 56 current holders: 17 (30%) held >2 years, 17 held 1–2 years, and 22 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

💎

Buying through price weakness — shares -15%, value -59%

Value

-59%

-15%

Last quarter: funds added -15% more shares while total portfolio value only changed -59%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

📊

Peak discovery — momentum slowing

12 → 16 → 16 → 10 → 12 new funds/Q

New funds entering each quarter: 16 → 16 → 10 → 12. JSPR is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.

📊

Mixed cohorts — 3% veterans, 41% new entrants

■ 3% veterans ■ 55% 1-2yr ■ 41% new

Of 58 current holders: 2 (3%) held 2+ years, 32 held 1–2 years, 24 (41%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

✅

Strong quality — 26% AUM from major funds

26% from top-100 AUM funds

16 of 55 holders rank in the top 100 by AUM, accounting for 26% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

2.3

out of 10

Low Exit Risk

Exit risk score 2.3/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	43	56	-23.21%
13F Shares	12M	16M	-22.79%
Total Value	$5M	$14M	-64.52%
New Positions	4	12	-8
Increased Positions	10	15	-5
Closed Positions	15	10	+5
Reduced Positions	14	13	+1
Total Calls	2	2	-
Total Puts	2	1	100.0%
PUT/CALL Ratio	1.0	0.5	Neutral

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

-23.21%

13F Shares

12M

16M

-22.79%

Total Value

$5M

$14M

-64.52%

New Positions

-8

Increased Positions

-5

Closed Positions

Reduced Positions

Total Calls

Total Puts

100.0%

PUT/CALL Ratio

1.0

0.5

Neutral

Institutional Holders (2026 Q2)

43 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in JSPR. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 JSPR holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Lion Point Capital, LP	0.94%	465,000	$196K
2	Velan Capital Investment Management LP	0.68%	2,668,395	$1.1M
3	Acorn Capital Advisors, LLC	0.16%	1,438,159	$604K
4	Kingdon Capital Management, L.L.C.	0.06%	1,352,106	$569K
5	Rock Springs Capital Management LP	0.02%	1,100,726	$463K
6	Diker Management LLC	0.01%	35,000	$15K
7	Quarry LP	0.00%	131,529	$55K
8	Carlyle Group Inc.	0.00%	1,066,189	$449K
9	ADAR1 Capital Management, LLC	0.00%	140,000	$59K
10	Sequent Planning LLC	0.00%	14,900	$6K
11	Ikarian Capital, LLC	0.00%	24,093	$10K
12	Rehmann Capital Advisory Group	0.00%	15,300	$6K
13	XTX Topco Ltd	0.00%	33,406	$14K
14	Renaissance Technologies LLC	0.00%	237,900	$100K
15	Tower Research Capital LLC (TRC)	0.00%	9,336	$4K
16	Jain Global LLC	0.00%	51,185	$22K
17	Millennium Management LLC	0.00%	486,933	$205K
18	Engineers Gate Manager LP	0.00%	12,989	$5K
19	Ieq Capital, LLC	0.00%	13,538	$6K
20	Osaic Holdings, INC.	0.00%	45,850	$19K
21	Vanguard Fiduciary Trust Co	0.00%	149,943	$63K
22	Qube Research & Technologies Ltd	0.00%	33,722	$14K
23	Group One Trading LLC	0.00%	19,930	$8K
24	Vanguard Capital Management LLC	0.00%	1,172,021	$493K
25	Citadel Advisors LLC	0.00%	206,000	$87K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Jasper Therapeutics Inc (JSPR)

What does the Smart Money Trend signal show for JSPR?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added JSPR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for JSPR?

Slight buying edge — 53% buying: Last quarter: 28 funds bought or added vs 25 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for JSPR holders?

Strong quality — 26% AUM from major funds: 16 of 55 holders rank in the top 100 by AUM, accounting for 26% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held JSPR?

Mixed — 30% long-term, 39% new: Of the 56 current holders: 17 (30%) held >2 years, 17 held 1–2 years, and 22 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Jasper Therapeutics Inc (JSPR) following the 2026 Q2 hedge fund 13F filings?

As of today, JSPR has moved -5.5% since the 2026 Q2 13F filing date (August 14, 2026), compared to +3.5% for the XLV sector ETF — an outperformance of -9.0%. Since the quarter end (June 30, 2026), JSPR has gained +77.3% vs +9.2% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Jasper Therapeutics Inc (JSPR)

Smart Money Signals — JSPR

Buying streak — 1 quarter in a row

Below peak — only 66% of 3.0Y high

Outflows — 16% fewer funds vs a year ago

Slight buying edge — 53% buying

Steady new buyers — ~12 new funds per quarter

Mixed — 30% long-term, 39% new

Buying through price weakness — shares -15%, value -59%

Peak discovery — momentum slowing

Mixed cohorts — 3% veterans, 41% new entrants

Strong quality — 26% AUM from major funds

Institutional Sentiment Summary — JSPR

Hedge Fund Ownership: JSPR

Market Analysis: JSPR

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: JSPR

Is It Too Late to Buy Jasper Therapeutics Inc (JSPR) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: JSPR

Statistics: JSPR

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Jasper Therapeutics Inc (JSPR)

Welcome to 13Foresight!